PMI

Picard is a single-product holding company whose entire business is SynCardia, maker of the only FDA-approved Total Artificial Heart (2,100+ implanted in 27 countries). The device is a genuine, differentiated asset — but the financials around it are broken. FY2025 revenue was just $4.94M (+12.5%), and the company lost money on the product itself: gross profit was NEGATIVE $204K, a -4.1% gross margin, with product cost of revenue ($3.43M) rising 38% against 12% product-revenue growth. A company that cannot sell its flagship above cost has no path to profitability from operating leverage alone; it must re-engineer unit economics before scale means anything. Net loss widened to -$27.0M from -$21.1M, operating loss was -$13.3M, and the accumulated deficit sits at -$76.8M.

The balance sheet turns this from 'high-risk growth' into a solvency question. Operating cash flow was -$15.7M against just $7.45M of cash — roughly six months of runway at the current burn. The cash cushion only exists because of the September 2, 2025 IPO (cash jumped 7,661% YoY and equity 'improved' to $3.79M via that raise, not operations). With liabilities/equity at 4.95x and burn outrunning cash, further dilution or financing is a near-certainty, and at a $12.7M market cap and $0.17 share price, existing holders face severe dilution risk. This is a going-concern profile dressed as a med-tech story.